Gestione del Covid-19 in età pediatrica: documento di consenso

Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33. 2. Bialek S, Gierke R, Hughes M, McNamara LA, Pilishvili T, Skoff T. Coronavirus Disease 2019 in Children - United States, February 12 - April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:422-6. 3. Castagnoli R, Votto M, Licari A, et al. Severe Acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection in children and adolescents: A systematic review. JAMA Pediatr 2020;174:882-9. 4. Dong Y, Dong Y, Mo X, et al. Epidemiology of Covid-19 among children in China. Pediatrics 145(6):e20200702. 5. Götzinger F, Santiago-García B, Noguera-Julián A, at al. Covid-19 Study Group. Covid-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Heal 2020;4:653-61. 6. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20:669-77. 7. Patel KP, Vunnam SR, Patel PA, et al. Transmission of SARS-CoV-2: an update of current literature. Eur J Clin Microbiol Infect Dis 2020;39:2005-11. 8. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with Covid-2019. Nature. 2020;581: 465-9. 9. European Centre for Disease Prevention and Control. Covid-19 testing strategies and objectives. 15 September 2020. ECDC: Stockholm; 2020. https://www.ecdc.europa. eu/en/publications-data/covid-19-testing-strategies-and-objectives. Ultimo accesso: 2 febbraio 2021. 10. Ludvigsson JF. Systematic review of Covid-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109:1088-95. 11. Deville JG. Coronavirus disease 2019 (Covid-19): Clinical manifestations and diagnosis in children. UpToDate aggiornato 19.01.2021 https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-clinical-manifestations-and-diagnosis-in-children?topicRef= 127454&source=see_link. Ultimo accesso: 2 febbraio 2021. 12. Rapporto ISS Covid-19 n. 63/2020 - Apertura delle scuole e andamento dei casi confermati di SARS-CoV-2: la situazione in Italia. Versione del 30 dicembre 2020. 13. European Centre for Disease Prevention and Control. Covid-19 in children and the role of school settings in transmission - first update (23 december). Stockholm, 2020. 14. Li X, Xu W, Dozier M, et al.; UNCOVER. The role of children in transmission of SARS-CoV-2: A rapid review. J Glob Health 2020;10: 011101. 15. Munro APS, Faust SN. Children are not Covid-19 super spreaders: time to go back to school. Arch Dis Child 2020;105:618-9. 16. Hsieh KY, Kao WT, Li DJ, et al. Mental health in biological disasters: From SARS to Covid-19. Int J Soc Psychiatry 2020, Jul 29 [Epub ahead of print]. 17. Esposito S, Giannitto N, Squarci A, et al. Development of psychological problems among adolescents during school closures because of the Covid-19 lockdown phase in Italy: a cross-sectional survey. Front Pediatr 2021, Jan 22 [Epub ahead of print]. 18. de Miranda DM, da Silva Athanasio B, Oliveira ACS, Simoes-e-Silva AC. How is Covid-19 pandemic impacting mental health of children and adolescents? Int J Disaster Risk Reduct 2020;51:101845. 19. Imai N, Gaythorpe KAM, Abbott S,et al. Adoption and impact of non-pharmaceutical interventions for Covid-19. Wellcome Open Res 2020;5:59. 20. Viner RM, Russell SJ, Croker H, et al. School closure and management practices during coronavirus outbreaks including Covid-19: a rapid systematic review. Lancet Child Adolesc Health 2020;4:397-404. 21. Singh S, Roy D, Sinha K, Parveen S, Sharma G, Joshi G. Impact of Covid-19 and lockdown on mental health of children and adolescents: A narrative review with recommendations. Psychiatry Res 2020;293:113429. 22. ECDC. Covid-19 in children and the role of school settings in transmission - first update. https://www.ecdc.europa.eu/en/publications-data/children-and-school-settings-covid-19-transmission. Ultimo accesso: 2 febbraio 2021. 23. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (Covid-19). https://www.cdc.gov/coronavirus/2019-nCoV/index.html. Ultimo accesso: 12 dicembre 2020. 24. World Health Organization. https://www. who.int/emergencies/diseases/novelcoronavirus- 2019/advice-for-public. Ultimo accesso: 12 dicembre 2020. 25 Ministero della Salute. http://www.salute. gov.it/portale/nuovocoronavirus/homeNuovoCoronavirus.jsp. Ultimo accesso: 12 dicembre 2020. 26. Cheng KK, Lam TH, Leung CC. Wearing face masks in the community during the Covid-19 pandemic: altruism and solidarity. Lancet 2020, Apr 16 [Epub ahead of print]. 27. Esposito S, Principi N, Leung CC, Migliori GB. Universal use of face masks for success against Covid-19: evidence and implications for prevention policies. Eur Respir J 2020;55: 2001260. 28. Hoang A, Chorath K, Moreira A, et al. Covid-19 in 7780 pediatric patients: A systematic review. E Clinical Medicine 2020;24:100433. 29. Centers for Disease Control and Prevention “information for pediatric heath care providers” www.cdc.gov/coronavirus/2019/ ncov/hcp/pediatric-hcp.html. Ultimo accesso: 12 dicembre, 2020. 30. Kuttiatt VS, Abraham PR, Menon RP, Vaidya PC, Rahi M. Coronavirus disease 2019 in children: Clinical & epidemiological implications. Indian J Med Res 2020;152:21-40. 31. Son MBF. Coronavirus disease 2019 (Covid-19): Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis. UpToDate aggiornato 25.09.2020 https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-multisystem-inflammatory-syndrome-in-children-mis-c-clinical-features-evaluation-and-diagnosis. Ultimo accesso: 2 febbraio 2021. 32. Circolare Ministero Salute 29 maggio 2020 - Ricerca e gestione dei contatti di casi Covid-19 (Contact tracing) e App Immuni. https:// www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=74178&parte=1%20&serie=null. Ultimo accesso: 2 febbraio 2021. 33. Huff HV, Singh A. Asymptomatic transmission during the Covid-19 pandemic and implications for public health strategies. Clin Infect Dis 2020, May 28 [Epub ahead of print]. 34. Circolare Ministero Salute 8 gennaio 2021 - Aggiornamento della definizione di caso Covid-19 e strategie di testing. https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=78155&parte=1%20&serie=null. Ultimo accesso: 2 febbraio 2021. 35. Lin EE, Blumberg TJ, Adler AC, et al. Incidence of Covid-19 in Pediatric Surgical Patients Among 3 US Children's Hospitals. JAMA Surg 2020; 155:775-777. 36. DECRETO-LEGGE 14 gennaio 2021, n. 2 Ulteriori disposizioni urgenti in materia di contenimento e prevenzione dell'emergenza epidemiologica da Covid-19 e di svolgimento delle elezioni per l'anno 2021. https://www. gazzettaufficiale.it/eli/id/2021/01/14/21G00002/sg. Ultimo accesso: 1 febbraio 2021. 37. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020;323:1843. 38. Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for Covid-19. https://www.cdc.gov/coronavirus/ 2019-ncov/lab/guidelines-clinical-specimens.html. Ultimo accesso: 12 dicembre 2020. 39. Donà D, Minotti C, Costenaro P, Da Dalt L, Giaquinto C. Fecal-oral transmission of SARSCov- 2 in children. Pediatr Infect Dis J 2020;39:e133-e134. 40. Palmas G, Moriondo M, Trapani S, et al. Nasal Swab as Preferred Clinical Specimen for Covid- 19 Testing in Children. Pediatr Infect Dis J 2020;39:e267-e270. 41. Capecchi E, Di Pietro GM, Luconi E; Testing Pediatric Covid-19 (TPC-19). Is Nasopharyngeal Swab Comparable With Nasopharyngeal Aspirate to Detect SARS-CoV-2 in Children? Pediatr Infect Dis J 2020;39:e288-e289. 42. Circolare Ministero Salute 12 ottobre 2020 - Trasmissione documento “Prevenzione e risposta a Covid-19: evoluzione della strategia e pianificazione nella fase di transizione per il periodo autunno-invernale. https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=76597&parte=1%20&serie=null. Ultimo accesso: 1 febbraio 2021. 43. Russo A, Minichini C, Starace M, Astorri R, Calò F, Coppola N; Vanvitelli Covid-19 group. Current Status of Laboratory Diagnosis for Covid-19: A Narrative Review. Infect Drug Resist 2020;13:2657-65. 44. CDC. Overview of Testing for SARS-CoV2 (Covid-19). Centers for Disease Control and Prevention, Atlanta, 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testingoverview. htlm. Ultimo accesso: 12 dicembre 2020. 45. Dinnes J, Deeks JJ, Adriano A, Berhane S, et al. Cochrane Covid-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2020;8:CD013705. 46. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. JAMA Netw Open 2020;3:e2016818. 47. Watson J, Whiting PF, Brush JE. Interpreting a Covid-19 test result. BMJ 2020;369: m1808. 48. Smith-Norowitz TA, Hammerschlag MR, Kohlhoff S. Coronavirus Disease 2019 (Covid-19) infection rates in a private school in Brooklyn, New York. Acta Paediatr 2021, Feb 1 [Epub ahead of print]. 49. Pecora ND, Zand MS. Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning. Clin Lab Med 2020;40:603-14. 50. Van Elslande J, Decru B, Jonckheere S, et al. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect 2020;26:1557.e1-1557.e7. 51. Chan K, Beck C, Chauvin-Kimoff L, et al.; Acute Care Committee POSITION STATEMENT of The Canadian Paediatric Society. The acute management of paediatric coronavirus disease 2019 (Covid-19). Available from: https://www.cps.ca/en/documents/position/the-acute-management-of-paediatric-coronavirus-disease-2019covid-19 Ultimo accesso: 12 dicembre 2020. 52. Venturini E, Montagnani C, Garazzino S, et al. Italian SITIP-SIP SARS-Cov-2 pediatric infection study group. Treatment of children with Covid-19: position paper of the Italian Society of Pediatric Infectious Disease. Ital J Pediatr 2020;46:139. 53. Garazzino S, Montagnani C, Donà D, et al. Italian SITIP-SIP Pediatric Infection Study Group; Italian SITIP-SIP SARS-CoV-2 paediatric infection study group. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill 2020;25:2000600. 54. Vergine G, Fantini M, Marchetti F, et al. Regione Emilia-Romagna Covid-19 Pediatric Working Group (RERCOPed). Home Management of Children With Covid-19 in the Emilia-Romagna Region, Italy. Front Pediatr 2020;8:575290. 55. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening Covid-19. Science 2020;370: eabd4570. 56. Marlais M, Wlodkowski T, Vivarelli M, et al. The severity of Covid-19 in children on immunosuppressive medication. Lancet Child Adolesc Health 2020;4:e17-e18. 57. Esposito S; Parma Covid-19 Pediatric Working Group (PaCoPed), Voccia E, et al. Telemedicine for management of paediatric infectious diseases during Covid-19 outbreak. J Clin Virol 2020;129:104522. 58. Paget J, Caini S, Cowling B, et al. The impact of influenza vaccination on the Covid-19 pandemic? Evidence and lessons for public health policies. Vaccine 2020;38:6485-6. 59. Nicastro E, Di Giorgio A, Zambelli M, et al. Impact of the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak on Pediatric Liver Transplant Recipients in Lombardy, Northern Italy. Liver Transpl 2020;26:1359-62. 60. Arrigo S, Alvisi P, Banzato C, et al. Management of paediatric IBD after the peak of Covid-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group. Dig Liver Dis 2021;53(2):183-9. 61. Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R; Pediatric Rheumatology Group of the Milan Area. Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs. J Rheumatol 2020, Apr 25 [Epub ahead of print]. 62. Koker O, Demirkan FG, Kayaalp G, et al. Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of Covid-19. Rheumatol Int 2020;40:1613-23. 63. Vasudevan A, Mantan M, Krishnamurthy S, et al. and the Indian Society of Pediatric Nephrology. Managing children with renal diseases during the Covid-19 pandemic. Indian Pediatr 2020;57:641-651. 64. Abrams EM, Szefler SJ. Manging asthma during coronavirus disease-2019: An example for other chronic conditions in children and adolescents. J Pediatr 2020;222:221-6. 65. Bezzerri V, Lucca F, Volpi S, Cipolli M. Does cystic fibrosis constitute an advantage in Covid-19 infection? It J Pediatr 2020;46: 143. 66. Balduzzi A, Brivio E, Rovelli A, et al. Lessons after the early management of the Covid-19 outbreak in a pediatric transplant ad hemato-oncology center embedded within a Covid-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone Marrow Transplant 2020;55:1900-1905. 67. Laventhal NT, Graham RJ, Rasmussen SA, Urion DK, Kang PB. Ethical decision-making for children with neuromuscular disorders in the Covid-19 crisis. Neurology 2020;95:260-265. 68. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes and Covid-19- related mortality in England: a whole population study. Lancet Diabetes Endocrinol 2020;11:965. 69. Selvin E, Juraschek SP. Diabetes Epidemiology in the Covid-19 Pandemic. Diabetes Care 2020;43:1690-4. 70. Kamrath CM, Mönkemöller K, Biester T, et al. Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the Covid-19 Pandemic in Germany. JAMA 2020;324:801-3. 71. Predieri B, Leo F, Candia F, et al. Glycemic Control improvement in Italian Children and Adolescents with Type 1 Diabetes followed through Telemedicine during Lockdown due to the Covid-19 Pandemic. Fronts Endocrinol 2020;11:965. 72. Bornstein SR, Rubino F, Khunti K, et al. Personal View Practical recommendations for the management of diabetes in patients with Covid-19. Lancet Diabetes Endocrinol 2020; 8:546-50. 73. Tresoldi AS, Sumilo D, Perrins M, et al. Increased infection risk in Addison’s disease and congenital adrenal hyperplasia. J Clin Endocrinol Metab 2020;105:418-29. 74.Hahner S, Spinnler C, Fassnacht M, et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab 2015;100:407- 16. 75. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:364-89. 76. Royal College of Pediatrics and Child Health. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with Covid-19. https://www.rcpch.ac.uk/resources/guidancepaediatric-multisystem-inflammatory-syndrometemporallyassociated- covid-19. Ultimo accesso: 12 dicembre 2020. 77. Center for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C). https://www.cdc.gov/ mis-c. Ultimo accesso: 12 dicembre 2020. 78. European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children - 15 May 2020. ECDC: Stockholm. Ultimo accesso: 12 dicembre 2020. 79. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARSCoV- 2 epidemic: an observational cohort study. Lancet 2020;6736:1-8. 80. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during Covid-19 pandemic. Lancet 2020;395:1607-8. 81. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with Covid-19. Published May 15, 2020. https://www.who.int/newsroom/ commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-withcovid- 19 Ultimo accesso: 12 dicembre 2020. 82. Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev 2020;S1526-0542(20)30117-2. 83. Greene AG, Saleh M, Roseman E, Sinert R. Toxic shock-like syndrome and Covid-19: a case report of multisystem m inflammatory syndrome in children (MIS-C). Am J Emerg Med 2020;1207:5-6. 84. Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the Covid-19 pandemic: a case series. J Pediatr Infect Dis 2020;9:393-8. 85. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the Covid-19 pandemic in Paris, France: prospective observational study. Br Med J 2020;369: 369:m2094. 86. Cheung EW, Zachariah P, Gorelik M, et al. Multisystem inflammatory syndrome related to Covid-19 in previously healthy children and adolescents in New York city. JAMA 2020; 324:294-6. 87. Whittaker E, Bamford A, Kenny J, et al.for the PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020;324:259-69. 88. Grimaud M, Starck J, Levy M, et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care 2020;10:69. 89. Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine 2020; 26:100527. 90. Waltuch T, Gill P, Zinns LE, et al. Features of Covid-19 post-infectious cytokine release syndrome in children presenting to the emergency department. Am J Emerg Med 2020;38: 2246.e3- 2246.e6. 91. Ramcharan T, Nolan O, Lai CY, et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARSCoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatr Cardiol 2020;41:1391-401. 92. Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SAR-SCoV- 2 mimicking Kawasaki disease (Kawa-Covid-19): a multicentre cohort. Ann Rheum Dis 2020;79:999-1006. 93. Kaushik S, Aydin SI, Derespina KR, et al. Multisystem inflammatory syndrome in children (MIS-C) associated with SARSCoV- 2 infection: a multi-institutional study from New York City. J Pediatr 2020;224:24-9. 94. Dufort EM, Koumans EH, Chow EJ, et al. for the New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York state. N Engl J Med 2020;383:347-58. 95. Feldstein LR, Rose EB, Horwitz SM, et al. for the Overcoming Covid-19 Investigators, and the CDC Covid-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020;383: 334-46. 96. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020;142:429-36. 97. Godfred-Cato S, Bryant B, Leung J, et al. Covid-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep 2020;69:1074-80. 98. Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMSTS) in the UK: a multicentre observational study. Lancet Child Adolesc Health 2020;4:669-77. 99. Lee PY, Day-Lewis M, Henderson LA, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest 2020;130:5942-50. 100. Deza Leon MP, Redzepi A, McGrath E, et al. Covid-19-Associated Pediatric Multisystem Inflammatory Syndrome. J Pediatric Infect Dis Soc 2020;9:407-8. 101. Rauf A, Vijayan A, John ST, Krishnan R, Latheef A. Multisystem Inflammatory Syndrome with Features of Atypical Kawasaki Disease during Covid-19 Pandemic. Indian J Pediatr 2020;87:745-7. 102. Ravelli A, Minoia F, Davì S, et al. Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/ American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;75:481-9. 103. AIFA. Principi di gestione dei casi di CoVID-19 nel setting domiciliare. https://www. aifa.gov.it/documents/20142/1269602/SOC_territoriale_09.12.2020.pdf/0f4896f4-1eac-32e2-bc26-5f5d279492b4. Ultimo accesso: 1 febbraio 2021. 104. European Medicines Agency. EMA gives advice on the use of non-steroidal antiinflammatories for Covid-19. Available from: https://www.ema.europa.eu/en/news/ema-givesadvice- use-non-steroidal-anti-inflammatories-covid-19. Ultimo accesso: 21 aprile 2020. 105. WHO. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with Covid- 19. Available from: https://www.who. int/publications/i/item/the-use-of-non-steroidal-antiinflammatory-drugs-(nsaids)-in-patients-with-covid-19. Ultimo accesso: 21 aprile 2020. 106. Martins-Filho PR, do Nascimento-Júnior EM, Santos VS. No current evidence supporting risk of using Ibuprofen in patients with Covid-19. Int J Clin Pract 2020;74:e13576. 107. Sodhi M, Etminan M. Safety of Ibuprofen in Patients With Covid-19: Causal or Confounded? Chest 2020;158:55-6. 108. AIFA. Trattamenti utilizzabili nei pazienti CoVID-19 nel setting ospedaliero. https:// www.aifa.gov.it/documents/20142/1269602/SOC_ospedaliera_09.12.2020.pdf/021a4ffe-7a80-32ed-ee9c-65a383ff1b47. Ultimo accesso: 1 febbraio 2021. 109. WHO. Modes of transmission of virus causing Covid-19: implication for IPC precaution recommendation. World Health Organization 2020. Available from: https://www. who.int/newsroom/commentaries/detail/ modes-of-transmission-of-virus-causing-covid-19-implications-for-ipcprecaution-recommendations. Ultimo accesso: 21 aprile 2020. 110. Leis JA, Born KB, Theriault G, Ostrow O, Grill A, Johnston KB. Using antibiotics wisely for respiratory tract infection in the era of Covid-19. BMJ 2020;371:m4125. 111. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with Covid-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020;26:1622-9. 112. Furtado RHM, Berwanger O, Fonseca HA, et al; COALITION Covid-19 Brazil II Investigators. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe Covid-19 in Brazil (COALITION II): a randomised clinical trial. Lancet 2020;396:959-67. 113. Oldenburg CE, Doan T. Azithromycin for severe Covid-19. Lancet 2020;396:936-7. 114. Lamontagne F, Agoritsas T, Macdonald H, et al. A living WHO guideline on drugs for Covid-19. BMJ 2020;370:m3379. 115. WHO Rapid Evidence Appraisal for Covid-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With Covid-19: A Meta-analysis. JAMA 2020;324:1330-41. 116. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med 2020, Jul 17 [Epub ahead of print]. 117. WHO. Corticosteroids for Covid-19. Living guidance. World Health Organization 2020. Available from: https://apps.who.int/ iris/handle/10665/334125. Ultimo accesso 21 aprile 2020. 118. AIFA. Corticosteroidi nella terapia dei pazienti adulti con Covid-19. https://www.aifa. gov.it/documents/20142/1123276/Corticosteroidi_06.10.2020.pdf/075c9302-895c-4d7e-11bc-0e2319082ffc. Ultimo accesso: 1 febbraio 2021. 119. Parr JB. Time to Reassess Tocilizumab’s Role in Covid-19 Pneumonia. JAMA Intern Med 2021;181(1):12-5. 120. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With Covid-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2021;181(1):32-40. 121. Pain CE, Felsenstein S, Cleary G, et al. Novel paediatric presentation of Covid-19 with ARDS and cytokine storm syndrome without respiratory symptoms. Lancet Rheumatol 2020;2:e376-e379. 122. Chen P, Nirula A, Hellen R et al, BLAZE-1 Investigators. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 2021;384(3):229-237. doi: 10.1056/NEJMoa2029849. 123. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate Covid-19: A Randomized Clinical Trial. JAMA 2021; Epub Jan 21. e210202. doi: 10.1001/jama.2021.0202. 124. AIFA- Parere CTS su anticorpi monoclonali: https://www.aifa.gov.it/documents/ 20142/1289678/parere_cts_monoclonali_04.02.2021.pdf/68737075-6f07-2a43-7f94-0bc55f2e38f1. 125. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 2020;383:517-25. 126. Mitjà O, Corbacho-Monné M, Ubals M, et al; BCN-PEP-CoV2 Research Group. A Cluster- Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med 2021;384(5):417-27. 127. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (Covid-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect 2021;27(1):19-27. 128. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2020, Dec 2 [Epub ahead of print]. 129. Simonovich VA, Burgos Pratx LD, Scibona P, et al. PlasmAr Study Group. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med 2020, Nov 24 [Epub ahead of print]. 130. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the Covid-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020;50:72-81. 131. Al-Ghafry M, Aygun B, Appiah-Kubi A, et al. Are children with SARS-CoV-2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients. Pediatr Blood Cancer 2020;67: e28737. 132. Loi M, Branchford B, Kim J, Self C, Nuss R. Covid-19 anticoagulation recommendations in children. Pediatr Blood Cancer 2020; 67:e28485. 133. Bhattacharyya R, Iyer P, Phua GC, Lee JH. The Interplay Between Coagulation and Inflammation Pathways in Covid-19-Associated Respiratory Failure: A Narrative Review. Pulm Ther 2020;6:215-31. 134. AIFA. Covid-19 - scheda informativa AIFA su eparine a basso peso molecolare. https:// www.aifa.gov.it/-/covid-19-scheda-informativa-aifa-su-eparine-a-basso-peso-molecolare. Ultimo accesso: 1 febbraio 2021. 135. Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for Covid-19- related illness. J Thromb Haemost 2020;18:3099-105. 136. Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter initial guidance on use of antivirals for children with Covid-19/SARS-CoV-2. J Pediatric Infect Dis Soc 2020, Sept 12 [Epub ahead of print]. 137. National Institute of Health. Coronavirus Disease 2019 (Covid-19) Treatment Guidelines. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguide lines. pdf. Ultimo accesso: 18 novembre 2020. 138. Eghbali. Covid-19 in pediatric patients: a case series. J Cell Mol Anesth. 2020;5:3. 139. AIFA. Scheda su Remdesivir. https:// www.aifa.gov.it/documents/20142/1123276/remdesivir_update01_24.11.2020.pdf/f600b68a-7aea-6781-3dbf-934db269087c. Ultimo accesso: 1 febbraio 2021. 140. Remdesivir. Food and Drug Administration. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf. Ultimo accesso il 18 novembre 2020. 141. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (Covid-19). Drug Discov Ther 2020;14:58-60. 142. AIFA. Scheda su Lopinavir/ritonavir https://www.aifa.gov.it/documents/20142/1123276/lopinavir_ritonavir_17.07.2020.pdf/ab9e07d8-585b-6eda-0007-a8f3d1e175c4. Ultimo accesso: 1 febbraio 2021. 143. AIFA. Scheda su Idrossiclorochina https://www.aifa.gov.it/documents/20142/1123276/idrossiclorochina+update05_22.12.2020.pdf/0d004070-a3e1-9aaa-7a0c-d30504fe19b8. Ultimo accesso: 1 febbraio 2021. 144. Harwood R, Allin B, Jones CE, et al.; PIMS-TS National Consensus Management Study Group. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with Covid-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health 2021;5(2):133-41. 145. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in Covid-19. Version 2. Arthritis Rheumatol 2020, Dec 5 [Epub ahead of print]. 146. Belhadjer Z, Méot M, Bajolle F, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation 2020;142:429-36. 147. Dufort EM, Koumans EH, Chow EJ et al; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med 2020;383:347-58. 148. Feldstein LR, Rose EB, Horwitz SM, et al. CDC Covid-19 Response Team. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med 2020;383:334-46. 149. Chen S, Dong Y, Kiuchi MG, Wang J, et al. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention: A Systematic Review and Meta-analysis. JAMA Pediatr 2016;170:1156-63. 150. Ouldali N, Toubiana J, Antona D, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. Published online February 01, 2021. doi:10.1001/jama.2021.0694. 151. Capone CA, Subramony A, Sweberg T, et al. Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Syndrome of Childhood Associated with severe acute respiratory syndrome coronavirus 2 Infection. J Pediatr 2020;224:141-5. 152. Kone-Paut I, Cimaz R, Herberg J, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series. Autoimmun Rev 2018;17: 768-74. 153. Marchesi A, Tarissi de Jacobis I, et al. Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. Ital J Pediatr 2018;44:103. 154. Ferrara G, Giani T, Caparello MC, Farella C, Gamalero L, Cimaz R. Anakinra for Treatment- Resistant Kawasaki Disease: Evidence from a Literature Review. Paediatr Drugs 2020;22:645-52. 155. de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology (Oxford) 2019;58:672-82. 156. Mahajan R, Lipton M, Broglie L, Jain NG, Uy NS. Eculizumab treatment for renal failure in a pediatric patient with Covid-19. J Nephrol 2020;33:1373-6. 157. Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel) 2020;7:69. 158. Chiang MH, Liu HE, Wang JL. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review. Arch Dis Child 2020, Nov 10 [Epub ahead of print]. 159. The European Parliament. European Charter for children in Hospital A.1. Off J Eur Commun. 1986; 37-38 Doc A2-25/86 (No. C 148). 160. Kache S, Chisti MJ, Gumbo F, et al. Covid-19 PICU guidelines: for high- and limited resource settings. Pediatr Res 2020;88:705-16 161. Walker DM, Tolentino VR. Covid-19: The impact on pediatric emergency care. Pediatr Emerg Med Pract 2020;17:1-27. 162. World Health Organization. Pocket Book for Hospital Care of Children: Guidelines for the Management of Common Illness with Limited Resources (World Health Organization, Geneva, 2013). 163. Khemani RG, Smith LS, Zimmerman JJ, Erickson S; Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med 2015;16: S23-40. 164. Davis AL, Carcillo JA, Aneja RK, et al. The American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: Executive Summary. Pediatr Crit Care Med 2017;18:884-90. 165. Workman JK, Ames SG, Reeder RW, et al. Treatment of Pediatric Septic Shock With the Surviving Sepsis Campaign Guidelines and PICU Patient Outcomes. Pediatr Crit Care Med 2016;17:e451-e458. 166. Health Advisory CDC. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (Covid-19). Atlanta, GA: CDC:2020. https:// emergency.cdc.gov/han/2020/han00432.asp?deliveryName=USCDC_511-DM28431 Ultimo accesso: 18 novembre 2020. 167. Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediartric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med 2015;16:428-39. 168. Kneyber MCJ, Medina A, Alapont VM, et al. Practice recommendations for the management of children with suspected or proven Covid-19 infections from the Paediatric Mechanical Ventilation Consensus Conference (PEMVECC) and the Section Respiratory Failure from the European Society for Paediatric and Neonatal Intensive Care (ESPNIC). https:// espniconline.org/Media/Files/2020- ESPNIC-PEMVECC-Covid-19-practice-recommendations. Ultimo accesso: 18 novembre 2020. 169. Hall D, Steel A, Heij R, Eley A, Young P. Videolaryngoscopy increases ‘mouth-to-mouth’ distance compared with direct laryngoscopy. Anaesthesia 2020;75:822-3. 170. Matava CT, Kovatsis PG, Lee JK, et al. PeDI-Collaborative. Pediatric Airway Management in Covid-19 Patients: Consensus Guidelines From the Society for Pediatric Anesthesia's Pediatric Difficult Intubation Collaborative and the Canadian Pediatric Anesthesia Society. Anesth Analg 2020;131:61-73. 171. Rimensberger PC, Cheifetz IM, Pediatric Acute Lung Injury Consensus Conference Group. Ventilatory support in children with pediatric acute respiratory distress syndrome: proceedings from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med 2015;16:S51-60. 172. Guérin C, Reignier J, Richard JC, et al. PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013;368:2159-68. 173. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatr Crit Care Med. 2020;21:e52-e106. 174. Tamburlini M, Marchetti F, Bertino E, et al. Bambini e coronavirus: la doverosa ricerca di un equilibrio tra i presunti rischi e di documentati effetti collaterali. Medico e Bambino 2020;39:355-6. 175. Loades ME, Chatburn E, Higson-Sweeney N, et al. Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of Covid-19. J Am Acad Child Adolesc Psychiatry 2020;59:1218-39.e3. 176. Marchetti F. Gli effetti avversi del Covid-19 in età pediatrica: la pandemia secondaria. Medico e Bambino pagine elettroniche 2020; 23:115-7. 177. Bignardi G, Dalmaijer ES, Anwyl-Irvine AL, et al. Longitudinal increases in childhood depression symptoms during the Covid-19 lockdown. Arch Dis Child. 2020, Dec 9 [Epub ahead of print]. 178. Wade M, Prime H, Browne DT. Why we need longitudinal mental health research with children and youth during (and after) the Covid-19 pandemic. Psychiatry Res 2020;290: 113143. 179. Tamburlini G. L’impatto della pandemia Covid-19 sulla salute globale dei bambini. Medico e Bambino 2020;39:629-32. 180. Circolare Ministero Salute 13 gennaio 2021- Idoneità sportiva agonistica in atleti non professionisti CoVID-19 positivi guariti e in atleti con sintomi suggestivi per CoVID-19 in assenza di diagnosi da SARS-CoV-2 http:// www.sport.governo.it/media/2422/circolare-idoneita-sportiva-np-covid-13-1-20.pdf. 181. Dean PN, Burns Jackson L, Paridon SN. Returning To Play After Coronavirus Infection: Pediatric Cardiologists' Perspectivehttps://www.acc.org/latest-in-cardiology/articles/2020/07/13/13/37/returning-to-play-after-coronavirus-infection. Ultimo accesso: 3 febbraio 2021. 182. Wade M, Prime H, Browne DT. Why we need longitudinal mental health research with children and youth during (and after) the Covid-19 pandemic. Psychiatry Res 2020;290: 113143